You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,830,661


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,830,661
Title: Diagnosis and treatment of glaucoma
Abstract:Methods of diagnosing glaucoma, and particularly primary congenital glaucoma, by detecting mutations in a gene associated with glaucoma, such as the CYP1B1 gene, are disclosed. Methods include hybridization analysis, such as Southern or Northern analysis, which use hybridization of a mutant nucleic acid probe to the gene associated with glaucoma; direct mutation analysis by restriction digest; sequencing of the gene associated with glaucoma; hybridization of an allele-specific oligonucleotide with amplified genomic DNA; or identification of the presence of mutant proteins encoded by the gene associated with glaucoma. Kits for use in diagnosis of glaucoma are also described. Methods of treatment of glaucoma, including administration of the protein encoded by the gene associated with glaucoma; administration of genes, gene constructs, or other nucleic acid constructs; or administration of other therapeutic agents, are additionally described.
Inventor(s): Sarfarazi; Mansoor (New Britain, CT)
Assignee: The University of Connecticut (Storrs, CT)
Application Number:08/800,036
Patent Claims:1. A method of diagnosing glaucoma in an individual, comprising detecting a mutation in a human cytochrome P4501B1 gene, wherein the presence of the mutation in the gene is indicative of glaucoma.

2. A method of diagnosing glaucoma in an individual, comprising the steps of:

a) obtaining a test sample of DNA containing human cytochrome P4501B1 gene from the individual; and

b) examining the test sample for the presence of a mutation in the human cytochrome P4501B1 gene,

wherein the presence of the mutation in the human cytochrome P4501B1 gene is indicative of glaucoma.

3. The method of claim 2, wherein the presence of the mutation in the human cytochrome P4501B1 gene is detected by direct mutation analysis by restriction digestion.

4. The method of claim 2, wherein the presence of the mutation in the human cytochrome P4501B1 gene is detected by hybridization of a nucleic acid probe to the human cytochrome P4501B1 gene in the test sample.

5. The method of claim 2, wherein the presence of the mutation in the human cytochrome P4501B1 gene is detected by hybridization of a peptide nucleic acid probe to the human cytochrome P4501B1 gene in the test sample.

6. The method of claim 2, wherein the presence of the mutation in the human cytochrome P4501B1 gene is detected by sequence analysis of the human cytochrome P4501B1 gene.

7. The method of claim 2, wherein the presence of the mutation in the human cytochrome P4501B1 gene is detected by hybridization of an allele-specific oligonucleotide with the human cytochrome P4501B1 gene in the test sample.

8. The method of claim 2, wherein the glaucoma is primary congenital glaucoma.

9. The method of claim 2, wherein the glaucoma is primary open angle glaucoma.

10. A method of diagnosing glaucoma in an individual, comprising the steps of:

a) obtaining from the individual a test sample of DNA comprising the human cytochrome P4501B1 gene;

b) contacting the test sample with at least one nucleic acid probe for mutant human cytochrome P4501B1 gene, thereby generating a hybridization sample;

c) maintaining the hybridization sample under conditions sufficient for specific hybridization of the human cytochrome P4501B1 gene with the nucleic acid probe for the mutant human cytochrome P4501B1 gene; and

d) detecting specific hybridization of the human cytochrome P4501B1 gene to the nucleic acid probe in the hybridization sample,

wherein the presence of specific hybridization of the human cytochrome P4501B1 gene to the nucleic acid probe is indicative of glaucoma.

11. A method of diagnosing glaucoma in an individual, comprising the steps of:

a) obtaining from the individual a test sample of DNA comprising the human cytochrome P4501B1 gene;

b) contacting the test sample with at least one peptide nucleic acid probe for mutant human cytochrome P4501B1 gene, thereby generating a hybridization sample;

c) maintaining the hybridization sample under conditions sufficient for specific hybridization of the human cytochrome P4501B1 gene with the peptide nucleic acid probe for the mutant human cytochrome P4501B1 gene; and

d) detecting specific hybridization of the human cytochrome P4501B1 gene to the peptide nucleic acid probe in the hybridization sample,

wherein the presence of specific hybridization of the human cytochrome P4501B1 gene to the peptide nucleic acid probe is indicative of glaucoma.

12. A method of diagnosing glaucoma in an individual, comprising the steps of:

a) obtaining from the individual a test sample of DNA comprising the human cytochrome P4501B1 gene;

b) determining the nucleic acid sequence of all or a fragment of the human cytochrome P4501B1 gene and

c) comparing the nucleic acid sequence of the human cytochrome P4501B1 gene or the fragment of the human cytochrome P4501B1 gene to a control sequence, wherein the presence of a mutation in the human cytochrome P4501B1 gene or fragment of the human cytochrome P4501B1 gene is indicative of a mutation associated with glaucoma.

13. A method of diagnosing primary congenital glaucoma in an individual, comprising detecting a mutation in the human cytochrome P4501B1 gene, wherein the presence of the mutation in the gene is indicative of primary congenital glaucoma.

14. The method of claim 13, wherein the mutation is a deletion of one or more nucleotides.

15. The method of claim 14, wherein the mutation is a deletion of nucleotides 1410-1422.

16. The method of claim 15, wherein the mutation is a deletion of nucleotide 1737.

17. The method of claim 14, wherein the mutation is a deletion of part of intron II and exon III.

18. The method of claim 13, wherein the mutation is the insertion of one or more nucleotides.

19. The method of claim 16, wherein the mutation is the insertion of a single cytosine residue in nucleotides 1209-1214.

20. The method of claim 13, wherein the mutation is a duplication of several nucleotides.

21. The method of claim 20, wherein the mutation is a duplication of nucleotides 1546-1555.

22. The method of claim 13, wherein the mutation is a change in one or more nucleotides.

23. The method of claim 22, wherein the mutation is a change of nucleotide 1482 from C to T.

24. The method of claim 22, wherein the mutation is a change of nucleotide 1188 from G to T.

25. A kit for use in diagnosing glaucoma, comprising a probe that specifically hybridizes to a mutant human cytochrome P4501B1 gene.

26. A nucleic acid probe that specifically hybridizes to a mutant human cytochrome P4501B1 gene.

27. A peptide nucleic acid probe that specifically hybridizes to a mutant human cytochrome P4501B1 gene.

Details for Patent 5,830,661

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.